/PRNewswire/ Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics.
/PRNewswire/ Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics.
Published: Feb 19, 2021 By Alex Keown
PICI – Bristol Myers Squibb veteran Ute Dugan was named Senior Vice President of Clinical Research at the Parker Institute for Cancer Immunotherapy (PICI). She will oversee PICI’s clinical development, regulatory affairs and translational medicine efforts, with a focus on overcoming immunotherapy resistance and advancing novel breakthrough treatment combinations. At BMS, she was head of Worldwide Oncology External Medical Affairs, where she created research collaboration models to advance immune-oncology treatments together with partners in academia, professional societies and non-profit organizations. Dugan originally joined BMS as executive director of Global Clinical Research during the formation of the development teams for the pioneering I-O medicines ipilimumab and nivolumab. Before that, her career included stints at Roche/Genentech and Aventis.
Corona: Novartis macht den Aargau zum globalen Impfstoff-Produzenten: Der Pharmakonzern will in Stein Wirkstoff abfüllen aargauerzeitung.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aargauerzeitung.ch Daily Mail and Mail on Sunday newspapers.